WO1997045542A3 - Cell growth regulatory genes - Google Patents

Cell growth regulatory genes Download PDF

Info

Publication number
WO1997045542A3
WO1997045542A3 PCT/US1997/009584 US9709584W WO9745542A3 WO 1997045542 A3 WO1997045542 A3 WO 1997045542A3 US 9709584 W US9709584 W US 9709584W WO 9745542 A3 WO9745542 A3 WO 9745542A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
cgr11
cgr19
cell growth
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/009584
Other languages
French (fr)
Other versions
WO1997045542A2 (en
Inventor
Gary A Beaudry
Arthur H Bertelsen
Elizabeth A Galella
Stephen I Madden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagenics Inc
Original Assignee
Pharmagenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagenics Inc filed Critical Pharmagenics Inc
Priority to EP97927946A priority Critical patent/EP0914338A2/en
Priority to CA002256498A priority patent/CA2256498A1/en
Priority to AU32281/97A priority patent/AU3228197A/en
Priority to JP09543058A priority patent/JP2000512494A/en
Publication of WO1997045542A2 publication Critical patent/WO1997045542A2/en
Publication of WO1997045542A3 publication Critical patent/WO1997045542A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y303/00—Hydrolases acting on ether bonds (3.3)
    • C12Y303/02—Ether hydrolases (3.3.2)
    • C12Y303/02009—Microsomal epoxide hydrolase (3.3.2.9), i.e. styreneepoxide hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Transcriptionally regulated growth-response genes play a pivotal role in the determination o a cell's fate. p53 is known to transcriptionally regulate genes important in regulating cell growth potential. Using differential RT-PCR analysis of rat embryo fibroblast cells containing a temperature-sensitive p53 allele, we were able to isolate several transcripts upregulated specifically in cells harboring the wild-type p53 protein. Two of these genes, SM20 and microsomal epoxide hydrolase (mEH), are previously described genes. Two previously uncharacterized cDNA's, cell growth regulatory (CGR) genes CGR11 and CGR19, were isolated. The predicted amino acid sequences of these novel proteins contain known motifs; EF-hand domains (CGR11) and a ring-finger domain (CGR19), are suggestive of function. CGR11 and CGR19 appear to be primary response genes expressed at 0.05 % and 0.01 % of the total mRNA in wild-type p53 cells. Both CGR11 and CGR19 as well as SM20 and mEH, are able to inhibit growth of several cell lines.
PCT/US1997/009584 1996-05-29 1997-05-29 Cell growth regulatory genes Ceased WO1997045542A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97927946A EP0914338A2 (en) 1996-05-29 1997-05-29 Cell growth regulatory genes
CA002256498A CA2256498A1 (en) 1996-05-29 1997-05-29 Cell growth regulatory genes
AU32281/97A AU3228197A (en) 1996-05-29 1997-05-29 Cell growth regulatory genes
JP09543058A JP2000512494A (en) 1996-05-29 1997-05-29 Cell growth regulatory gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1855796P 1996-05-29 1996-05-29
US60/018,557 1996-05-29

Publications (2)

Publication Number Publication Date
WO1997045542A2 WO1997045542A2 (en) 1997-12-04
WO1997045542A3 true WO1997045542A3 (en) 1998-05-07

Family

ID=21788559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009584 Ceased WO1997045542A2 (en) 1996-05-29 1997-05-29 Cell growth regulatory genes

Country Status (5)

Country Link
EP (1) EP0914338A2 (en)
JP (1) JP2000512494A (en)
AU (1) AU3228197A (en)
CA (1) CA2256498A1 (en)
WO (1) WO1997045542A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
JP2001517442A (en) * 1997-09-22 2001-10-09 インサイト・ファーマスーティカルズ・インコーポレイテッド Cell growth regulator
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
US7745579B1 (en) 1998-09-01 2010-06-29 David Wallach Inhibitor of NF-KB activation
GB0109008D0 (en) * 2001-04-10 2001-05-30 Oxford Biomedica Ltd Novel genes
JPWO2006098304A1 (en) * 2005-03-15 2008-08-21 国立大学法人埼玉大学 Novel secreted proteins derived from pituitary cells and their uses
JP2008063244A (en) * 2006-09-05 2008-03-21 Saitama Univ Treatment or prevention of abnormal glucose metabolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013375A1 (en) * 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
WO1996001907A1 (en) * 1994-07-12 1996-01-25 Bristol-Myers Squibb Company NOVEL p53 RESPONSE GENES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013375A1 (en) * 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
WO1996001907A1 (en) * 1994-07-12 1996-01-25 Bristol-Myers Squibb Company NOVEL p53 RESPONSE GENES

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAUER D. ET AL.: "Identification of differentially expressed mRNA species by an improved display technique.", NUCLEIC ACIDS RESEARCH, vol. 21, no. 18, 1993, pages 4272 - 4280, XP000394394 *
BUCKBINDER L. ET AL.: "Gene regulation by temperature-sensitive p53 mutants: Identification of p53 response genes.", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 10640 - 10644, XP002046023 *
EL-DEIRY W.S. ET AL.: "WAF1, a potential mediator of p53 tumor suppression.", CELL, vol. 75, 1993, pages 817 - 825, XP002046022 *
EMBL database entry HS52516; accession number T33525; 9. September 1995; Adams M.D. et al.: 'Initial assessment of human gene diver- sity and expression patterns based upon 52million basepairs of cDNA sequence.' *
MADDEN S.L. ET AL.: "Induction of cell growth regulatory genes by p53.", CANCER RESEARCH, vol. 56, 1 December 1996 (1996-12-01), pages 5384 - 5390, XP002046025 *
MICHALOVITZ D. ET AL.: "Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.", CELL, vol. 62, 1990, pages 671 - 680, XP002046026 *
OKAMOTO K. AND BEACH D.: "Cyclin G is a transcriptional target of the p53 tumor suppressor protein.", EMBO JOURNAL, vol. 13, no. 19, 1994, pages 4816 - 4822, XP002046024 *

Also Published As

Publication number Publication date
AU3228197A (en) 1998-01-05
WO1997045542A2 (en) 1997-12-04
CA2256498A1 (en) 1997-12-04
JP2000512494A (en) 2000-09-26
EP0914338A2 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
Baumhueter et al. HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF.
Fiol et al. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression.
Bois-Joyeux et al. Members of the CAAT/enhancer-binding protein, hepatocyte nuclear factor-1 and nuclear factor-1 families can differentially modulate the activities of the rat α-fetoprotein promoter and enhancer
Dugimont et al. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53
Chabes et al. S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region
Zhang et al. Localization of DNA protein-binding sites in the proximal and distal promoter regions of the mouse alpha-fetoprotein gene.
Vallejo et al. Somatostatin gene upstream enhancer element activated by a protein complex consisting of CREB, Isl-1-like, and alpha-CBF-like transcription factors.
Kaya et al. Human δ-aminolevulinate dehydratase (ALAD) gene: Structure and alternative splicing of the erythroid and housekeeping mRNAs
Johnston et al. Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-binding protein
CA2228635A1 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
Shaskus et al. A bifunctional genetic regulatory element of the rat dopamine beta-hydroxylase gene influences cell type specificity and second messenger-mediated transcription.
Li et al. Two adjacent C/EBP-binding sequences that participate in the cell-specific expression of the mouse serum amyloid A3 gene
Tulchinsky et al. Transcriptional regulation of the mts1 gene in human lymphoma cells: the role of DNA-methylation
Giddings et al. Rat insulin II gene expression by extraplacental membranes: a non-pancreatic source for fetal insulin
Wight et al. The first intron of the myelin proteolipid protein gene confers cell type-specific expression by a transcriptional repression mechanism in non-expressing cell types
Mariniello et al. Keratinocyte Transglutaminase Promoter Analysis:: IDENTIFICATION OF A FUNCTIONAL RESPONSE ELEMENT
Zhang Characterization of the 5′ flanking region of the human MnSOD gene
Argenton et al. The transcriptional regulation of the growth hormone gene is conserved in vertebrate evolution
Kazunori et al. Epoc-1: a POU-domain gene expressed in murine epidermal basal cells and thymic stromal cells
Cassuto et al. Involvement of HNF-1 in the regulation of phosphoenolpyruvate carboxykinase gene expression in the kidney
Boulter et al. The effects of v-src expression on the differentiation of embryonal carcinoma cells
Kim et al. Unique sequence organization and erythroid cell-specific nuclear factor-binding of mammalian Θ I globin promoters
Liu et al. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene transcription
Borrello et al. Manganese deficiency and transcriptional regulation of mitochondrial superoxide dismutase in hepatomas
Wang et al. The p69/71 2-5A synthetase promoter contains multiple regulatory elements required for interferon-α-induced expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2256498

Country of ref document: CA

Ref country code: CA

Ref document number: 2256498

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997927946

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997927946

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997927946

Country of ref document: EP